James N. Ingle

TL;DR: Significant increases in total cholesterol, HDL cholesterol, LDL cholesterol, and, most notably, Lp(a) in postmenopausal women were observed following 5 years of adjuvant letrozole treatment and after 5 years of tamoxifen therapy and such patients should have monitoring of their lipid levels in clinical practice.

TL;DR: It can be concluded that the addition of tamoxifen to CFP does not substantially improve either the time to disease progression or survival in women with metastatic breast cancer.

TL;DR: In this paper, the authors investigated the effect of single nucleotide polymorphisms (SNPs) near the TCL1A gene on NF-κB transcriptional activity and showed that this SNPdependent regulation could be reversed by selective ER modulators.

TL;DR: The clinician caring for women with early breast cancer is keenly aware of the variability observed when endocrine therapy with tamoxifen or the aromatase inhibitors (AIs) is employed, in which some women develop disabling musculoskeletal events that result in their discontinuing therapy, whereas the majority develops no such adverse events.